Atlanta, GA, United States of America

Michael Thomas Morgan

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.7

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michael Thomas Morgan: Innovator in Neuronal Injury Treatment

Introduction

Michael Thomas Morgan is an accomplished inventor based in Atlanta, GA (US). He holds 2 patents that focus on innovative methods and compositions for treating neuronal injuries and developing advanced imaging techniques. His work has significant implications in the fields of neuroscience and medical imaging.

Latest Patents

Morgan's latest patents include "Compositions and methods of treating neuronal injury," which features methods and compositions directed at treating neuronal injury, CNS lesions, and promoting axon regeneration using a phosphine sulfide-stabilized phosphine. Another notable patent is "Zinc-selective fluorescent probes for emission-ratiometric imaging," which relates to zinc-sensitive fluorescent probes and methods utilizing these compounds. These compounds provide an emission-ratiometric fluorescence response upon binding of an analyte and can be used for two-photon excitation microscopy or conventional fluorescence microscopy.

Career Highlights

Throughout his career, Morgan has worked with reputable organizations such as Georgia Tech Research Corporation and Children's Medical Center Corporation. His contributions to these institutions have helped advance research in medical technology and neuroscience.

Collaborations

Morgan has collaborated with notable colleagues, including Christoph J. Fahrni and Adam M. McCallum. Their joint efforts have furthered the development of innovative solutions in their respective fields.

Conclusion

Michael Thomas Morgan is a significant figure in the realm of inventions related to neuronal injury treatment and imaging technologies. His patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…